Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Etropal AD's revenue for the
three
months ended in Dec. 2025 was €10.38 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €10.38 Mil.
Etropal AD's Revenue per Share for the
three
months ended in Dec. 2025 was €2.08.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €2.08.
During the past 12 months, the average Revenue per Share Growth Rate of Etropal AD was 27.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 44.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 19.60% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 7.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Etropal AD's highest 3-Year average Revenue per Share Growth Rate was 44.20% per year. The lowest was -7.50% per year. And the median was 1.60% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Etropal AD Revenue Related Terms
Etropal AD Revenue Historical Data
* Premium members only.
The historical data trend for Etropal AD's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Etropal AD's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Etropal AD Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Etropal AD's Revenue distribution charts can be found below:
* The bar in red indicates where Etropal AD's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €10.38 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Etropal AD (XBUL:ETR) has a Revenue of €10.38 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Etropal AD and its competitors.
Is Etropal AD's Revenue too high?
Etropal AD's current Revenue is €10.38 Mil. Overall, Etropal AD has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Etropal AD's Revenue compare to ISRG and BDX?
Etropal AD's Revenue of €10.38 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Etropal AD and its competitors. Etropal AD's current Revenue is €10.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Etropal AD stock overvalued right now?
Based on GuruFocus' analysis, Etropal AD (XBUL:ETR) is currently considered Significantly Undervalued. The stock's GF Value™ is €8.87, compared to a current price of €2.62 — trading 70.5% below its estimated fair value. The current Revenue is €10.38 Mil. Etropal AD's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Etropal AD (XBUL:ETR), the current Revenue is €10.38 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Etropal AD (XBUL:ETR) Overvalued in 2026?
Based on GuruFocus' analysis, Etropal AD stock appears to be undervalued.
The current stock price of €2.62 is trading 70.5% below its estimated GF Value™ of €8.87.
GuruFocus considers Etropal AD to be Significantly Undervalued.
Key valuation signals for XBUL:ETR:
Revenue: €10.38 Mil
GF Value™: €8.87 vs. price of €2.62 (70.5% below fair value)
No single metric tells the full story. See the XBUL:ETR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Etropal AD is engaged in the business of manufacturing medical accessories. The product portfolio includes fistula needles, blood taking sets, transfusion and infusion sets, catheters and tubes, urine collecting bags, colostomy bags, among others. The company also produces hip - joint endoprosthesis and instruments of implantation.
50GF Score
Get the complete analysis for XBUL:ETR
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBUL:ETR has been successfully added to your 
